Company
Every investor coverage indicates participated in a round Que Oncology raised.
Investors whose own portfolio pages list Que Oncology, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Companies Que Oncology acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Julie Cherrington | Board Member | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Dr Rob Crombie | Chief Executive Officer | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Elizabeth Cermak | Board Member | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Que Oncology. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech company QUE Oncology adds two experienced pharmaceutical executives, Julie Cherrington and Elizabeth Cermak, to its board as it develops a non-hormonal breast cancer therapy.
Clinical-stage biotech QUE Oncology adds two experienced life science executives, Julie Cherrington and Elizabeth Cermak, to its board, while continuing trials of its non-hormonal therapy for breast cancer hot flashes.
Brandon Capital's blog reports a first close of $210 million toward its $250 million MRCF 5 biotech fund, with super funds and CSL backing, and recalls past portfolio sales of Spinifex and Fibrotech.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily